 Participants diagnosed as having MGUS will be randomized to three different arms, of which two arms will be called into a clinical study center for two separate types of follow-up. In arm one the participants will be asked to answer an electronic QoL questionnaire annually but receive no active follow-up. In arm two and three the participants will be asked to answer the QoL questionnaire but also receive follow-up according to the International Myeloma Working Group IMWG guidelines arm two or intensive arm three clinical follow-up. Participants without MGUS will be asked to answer QoL questionnaire annually. 